Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06389760 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 31, 2024 (before its estimated September 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Enrollment target: 50 to 57 Interventions: Nimotuzumab (Drug), mFOLFIRINOX (Drug) to GX (Drug), Nimotuzumab (Drug), mFOLFIRINOX (Drug) · Eligibility criteria shortened, about 73 words · Secondary endpoints: 6 to 2 · 2 morev2 Show 5 more changesShow less
    • Interventions: Nimotuzumab (Drug), mFOLFIRINOX (Drug) to GX (Drug), Nimotuzumab (Drug), mFOLFIRINOX (Drug)
    • Eligibility criteria shortened, about 73 words
    • Secondary endpoints: 6 to 2
    • Study description shortened, about 11 words
    • Study title shortened, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a prospective, multicenter, single-arm, open-label study. The main purpose of the study is to evaluate the efficacy and safety of Nimotuzumab combined with mFOLFIRINOX/GX for postoperative adjuvant treatment of pancreatic cancer.
Trial Details
NCT Number NCT06389760
Lead Sponsor The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Conditions Pancreatic Cancer
Enrollment 57 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov